Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Ongoing Initiated Jul 29, 2021 (5 years ago)

Erythromycin Topical Solution USP

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Defective container: possibility for lack of seal integrity.

Cause type: Packaging defect

Failed child-resistant closures, leaks, cracked containers, or a defective delivery device. Packaging failures risk accidental exposure (especially to children) or product contamination. All packaging defect recalls.

What was recalled

Erythromycin Topical Solution USP, 2%, 60mL bottle, Rx only, Teligent Pharma, Inc. Buena, NJ 08310, NDC 52565-027-59

Affected NDC 52565-0027-59

Compare with the code on your package — it is the most precise check available.

Drug: Erythromycin

Recalling firm
Teligent Pharma, Inc.
NDC code
52565-027-59
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0769-2021 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall.

Other Erythromycin recalls

See all
Class II · Moderate risk

Erythromycin Tablets

CGMP Deviations; presence of N-Nitroso-Desmethyl-Erythromycin above the recommended acceptable intake limit

Ongoing Nitrosamine impurity Zydus Pharmaceuticals (USA) Inc NDC 70710-1048-3 D-0545-2026
Class II · Moderate risk

Erythromycin Tablets

CGMP Deviations; presence of N-Nitroso-Desmethyl-Erythromycin above the recommended acceptable intake limit

Ongoing Nitrosamine impurity Zydus Pharmaceuticals (USA) Inc NDC 70710-1047-3 D-0544-2026
Class II · Moderate risk

Erythromycin Topical Gel USP

CGMP Deviations: all products within expiry are being recalled because the manufacturing firm, Teligent Pharma, Inc.is discontinuing its stability study program.

Ongoing Stability / shelf life McKesson Corporation dba McKesson Drug Company NDC 63739-053-68 D-0851-2022

Other recalls by Teligent Pharma, Inc.

All 2021 recalls
Class II · Moderate risk

Lidocaine Ointment USP

cGMP deviations: all products within expiry are being recalled because the firm is discontinuing its stability study program.

Terminated Stability / shelf life Teligent Pharma, Inc. NDC 50383-341-35 D-0705-2022
Class II · Moderate risk

Lidocaine Cream 4%

cGMP deviations: all products within expiry are being recalled because the firm is discontinuing its stability study program.

Terminated Stability / shelf life Teligent Pharma, Inc. NDC 0536-1281-28 D-0704-2022
Class II · Moderate risk

Hydrocortisone Butyrate Lotion

cGMP deviations: all products within expiry are being recalled because the firm is discontinuing its stability study program.

Terminated Stability / shelf life Teligent Pharma, Inc. NDC 70512-032-04 D-0703-2022
Class II · Moderate risk

Gentamicin Sulfate Cream USP

cGMP deviations: all products within expiry are being recalled because the firm is discontinuing its stability study program.

Terminated Stability / shelf life Teligent Pharma, Inc. NDC 70512-036-30 D-0702-2022